MAPT and Alzheimer disease: Subsequently, immunohistochemistry of brain sections from an AD patient and a JNPL3 mouse revealed that both antibodies recognize tau pathology, with 5G2 resulting in stronger staining than 1G11, with no staining detected in the control human brain or wild-type mouse brain (Figures 1B–1M).